Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/17/24
End: 07/31/29
Due: 07/31/30
Phase: N/A
Priority: Normal
Start: 06/30/25
End: 12/31/30
Due: 12/31/31
Phase: N/A
Priority: Normal
Start: 08/23/24
End: 03/31/27
Due: 03/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease | NCT06167681 | iRegene Therapeutics Co., Ltd. | user2@example.com | None | 2024-01-17 | 2029-07-31 | 2030-07-31 | - | - | 2025-07-14 |
| The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease | NCT07028632 | iRegene Therapeutics Co., Ltd. | user2@example.com | None | 2025-06-30 | 2030-12-31 | 2031-12-31 | - | - | 2025-07-14 |
| The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease | NCT06608355 | iRegene Therapeutics Co., Ltd. | user2@example.com | None | 2024-08-23 | 2027-03-31 | 2028-03-31 | - | - | 2025-07-14 |